| Verified against primary record | |
| European opioid treatment | An estimated 511,000 of 860,000 high-risk opioid users in the EU were receiving agonist treatment, 2023[1] |
|---|---|
| Provision varies | Described as low and insufficient in several named member states[1] |
| Records read | European drug agency report, reference year 2023, read 30 September 2026 |
| Independently reported | |
| Travel for this treatment | Not measured in any source located |
| Bands apply only to the rows beneath them. The treatment figures describe opioid agonist treatment within European health systems and say nothing about residential rehabilitation, private facilities or travel. | |
Addiction treatment abroad describes travel to another country for treatment of a substance use disorder, most visibly to residential rehabilitation facilities that market internationally. This entry is deliberately short. Most of what is usually written on the subject could not be verified against a primary source, and the honest course is to set out what was established and name what was not.
What is established
Treatment provision varies sharply between countries even within a single regulatory bloc, which is the structural condition that makes travel conceivable. The European drug agency reports that for 2023, more than half of the estimated 860,000 high-risk opioid users in the European Union, an estimated 511,000, were receiving opioid agonist treatment, rising to 523,000 including Norway and Turkey. Of the medications used, methadone accounted for more than half at 55 per cent, buprenorphine for another 35 per cent, and slow-release morphine or heroin-assisted treatment for 10 per cent.[1]
The same report records that levels of provision remain low and insufficient in some countries, naming Latvia, Lithuania, Poland, Romania and Slovakia. Among people in treatment, nearly 70 per cent were aged 40 or older and fewer than 10 per cent were under 30, and about 64 per cent had referred themselves, with 23 per cent referred by health or social services and 7 per cent through criminal justice.[1]
The scope of those figures should be stated plainly. They describe one form of treatment, opioid agonist treatment, delivered within European public health systems. They say nothing about residential rehabilitation, nothing about private facilities, and nothing about patients crossing borders. What they establish is that the availability of treatment differs by country, not that anyone travels in response.
What could not be established
Three things ordinarily said about this subject were not verified for this entry, and are therefore not stated here as fact.
The first is the global treatment gap. Figures of the form that only a small fraction of people with drug use disorders receive treatment circulate widely and are attributed to United Nations drug reporting. The relevant documents could not be opened, so no such figure appears here. It should not be repeated without being traced to the report that states it and the year it describes.
The second is whether any country licenses or regulates residential rehabilitation facilities that market to foreign patients. No source addressing this was located, in either direction. Given that accreditation and licensing are the main assurances a prospective patient has, this is a substantial gap in the public record rather than a minor one.
The third is the legal status of particular interventions that are permitted in some jurisdictions and prohibited in others, which is one of the stated reasons for this travel. No source on the legal position of any such intervention in any jurisdiction was opened, so none is described.
Nothing located measures how many people travel abroad for addiction treatment.
See also
- Mental health treatment abroad, the closely related field with the same provision gradient
- Rehabilitation abroad, a different sense of the same word
- Medical travel for unavailable treatments, where legal availability differs between countries
- Self-funded medical travel, the payment route this sector runs on
References
- European Union Drugs Agency. Opioid agonist treatment: the current situation in Europe, European Drug Report 2025. Reference year 2023. Verified against primary record: agency report opened and read. Retrieved 30 September 2026.
Sourcing note: the European drug agency report was opened and read on 30 September 2026 and is the only source used. Three strands ordinarily covered in writing on this subject are named as unverified rather than filled from general knowledge: the global treatment gap figure, the regulation of residential facilities marketing internationally, and the legal status of interventions permitted in some countries and not others. A later edition of the agency report exists and will supersede the 2023 reference year used here. This entry describes provision and law; it is not guidance on treatment and recommends no facility or intervention.